Woman and Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
Primary Objective: To demonstrate the reduction of low-density lipoprotein cholesterol (LDL-C) by alirocumab in comparison to ezetimibe as add-on therapy to stable maximally tolerated daily statin therapy in high cardiovascular (CV) risk patients with hypercholesterolemia in Asia. Secondary Objectives: - To evaluate the effect of alirocumab on other lipid parameters: eg, Apolipoprotein (Apo) B, non-HDL-C, total cholesterol (TC), lipoprotein a (Lp[a]), high-density lipoprotein cholesterol (HDL-C), triglycerides (TG), and Apo A-1. - To evaluate the safety and tolerability of alirocumab. - To evaluate the development of anti-alirocumab antibodies. - To evaluate the pharmacokinetics (PK) of alirocumab.
Inclusion criteria
- Hypercholesterolemia